LP64672-6
Natalizumab Ab
Active
Description
Drug therapy for MS - loses effectiveness when patients develop antibodies to the drug. Detecting the antibodies early allows healthcare providers the opportunity to prescribe alternative therapy and avoid the cost associated with failed therapy. Source: Regenstrief Institute
Basic Part Properties
- Part Display Name
- Natalizumab Ab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2007-07-17
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP64672-6
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| zh-CN | Chinese (China) | 那他珠单抗抗体 Synonyms: Natalizumab Ab; |
| pl-PL | Polish (Poland) | Natalizumab Ab Synonyms: Natalizumab |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright